CVS Group (LON:CVSG) Stock Rating Reaffirmed as Hold by Shore Capital Group

CVS Group (LON:CVSG)‘s stock had its “hold” rating reiterated by equities researchers at Shore Capital Group in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a GBX 1,400 target price on the stock. Shore Capital Group’s price target points to a potential upside of 15.89% from the stock’s current price.

A number of other research analysts also recently weighed in on the company. Jefferies Financial Group increased their target price on CVS Group from GBX 1,350 to GBX 1,400 and gave the company a “hold” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,700 price target on shares of CVS Group in a research note on Monday, July 27th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,000 price target on shares of CVS Group in a research report on Thursday. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,666.67.

CVS Group Price Performance

Shares of CVSG opened at GBX 1,208 on Thursday. The firm has a fifty day simple moving average of GBX 1,287.09 and a two-hundred day simple moving average of GBX 1,229.43. The firm has a market cap of £821.08 million, a PE ratio of 17.53, a P/E/G ratio of 1.77 and a beta of 1.07. The company has a current ratio of 1.18, a quick ratio of 0.90 and a debt-to-equity ratio of 110.41. CVS Group has a 1-year low of GBX 1,062 and a 1-year high of GBX 1,648.

CVS Group (LON:CVSG) last released its quarterly earnings results on Thursday, September 24th. The company reported GBX 85.60 earnings per share (EPS) for the quarter. CVS Group had a return on equity of 5.91% and a net margin of 2.43%. On average, equities analysts anticipate that CVS Group will post 93.9393939 EPS for the current year.

Insider Buying and Selling

In related news, insider Joanne Shaw purchased 1,592 shares of CVS Group stock in a transaction on Monday, August 10th. The shares were bought at an average cost of GBX 1,287 per share, for a total transaction of £20,489.04. Also, insider Robin Alfonso bought 768 shares of CVS Group stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of GBX 1,294 per share, for a total transaction of £9,937.92. Over the last 90 days, insiders acquired 3,860 shares of company stock worth $4,956,696. 1.48% of the stock is owned by corporate insiders.

Trending Headlines about CVS Group

Here are the key news stories impacting CVS Group this week:

• Positive Sentiment: Dividend supported by shareholder returns: CVS Group recommended a final dividend for the year ended June 30, 2026, payable on December 4, providing an income component for investors. CVS Group recommends final dividend
• Positive Sentiment: Insider purchase offers a modest confidence signal: Non-executive director Laura Hagan bought 4,128 CVS Group shares. The transaction may reassure investors about management’s view of the company’s valuation, although its financial impact is limited. CVS Group director share purchase
• Positive Sentiment: Berenberg maintained a Buy rating and a GBX 2,000 price target, implying substantial upside from the stock’s recent trading level. Berenberg rating update
• Neutral Sentiment: Full-year results were released: CVS Group reported GBX 85.60 in earnings per share, alongside a 2.31% net margin and 5.35% return on equity. The figures provide a fresh performance update, but the relatively low profitability metrics may limit enthusiasm without further detail on growth and costs. CVS Group full-year earnings results
• Negative Sentiment: Analyst caution remains the main pressure: Shore Capital reaffirmed its Hold rating and GBX 1,400 target, while Jefferies also maintained Hold with the same target. The repeated neutral recommendations suggest limited near-term conviction despite the higher Berenberg target. Shore Capital Hold rating

CVS Group Company Profile

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates from over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business (“Animed Direct”).

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.